GV and Illumina Ventures returned to reinvest in cellular therapy developer SQZ Biotechnologies, which has now raised at least $166m to date.

US-based cellular vaccine developer SQZ Biotechnologies closed a $65m series D round on Monday that included GV and Illumina Ventures, respective investment subsidiaries of internet technology conglomerate Alphabet and genomics technology producer Illumina.

The round was led by Singaporean government-owned investment firm Temasek and also featured NanoDimension, Polaris Partners, an unnamed US-based fund and JDRF T1D Fund, which is managed by diabetes-focused charity JRDF.

Spun out of Massachusetts Institute of Technology in 2013, SQZ is working on cell therapies that…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn